Physiologic response to the inotropic and vasodilator properties of enoximone

Joseph S. Janicki, Sanjeev G. Shroff, Karl Weber

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In patients with chronic cardiac failure, improvement in ventricular function is observed after the administration of enoximone, a phosphodiesterase inhibitor with inotropic and vasodilator properties. The relative contributions of positive inotropy and vasodilation to the improvement in pump performance, however, remain uncertain. Therefore, findings from a series of dog experiments designed to resolve this issue are reviewed. Also, our current understanding of the physiologic response to enoximone in patients with cardiac failure, including the responses of myocardial oxygen consumption and efficiency, are considered. It is concluded that, enoximone produces a substantial (66 ± 2% in dogs) increase in contractility, a relatively minor increase in heart rate (0 to 12%) and a decrease in systemic vascular resistance (-28 to -49%). These are the ranges of average responses based on review of published findings. These physiologic responses lead to an improvement in the pumping function of the failing heart; cardiac output (23 to 83%) and stroke work index (17 to 88%) are increased, and pulmonary capillary wedge pressure (-19 to -59%) and right atrial pressure (-29 to -60%) are decreased. The influence of enoximone on myocardial oxygen consumption is less consistent (-18 to +33%). Nevertheless, enoximone improves the efficiency of the failing heart.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalThe American journal of cardiology
Volume60
Issue number5
DOIs
StatePublished - Aug 14 1987
Externally publishedYes

Fingerprint

Enoximone
Vasodilator Agents
Oxygen Consumption
Heart Failure
Dogs
Pulmonary Wedge Pressure
Atrial Pressure
Phosphodiesterase Inhibitors
Ventricular Function
Vasodilation
Cardiac Output
Vascular Resistance
Heart Rate
Stroke

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Physiologic response to the inotropic and vasodilator properties of enoximone. / Janicki, Joseph S.; Shroff, Sanjeev G.; Weber, Karl.

In: The American journal of cardiology, Vol. 60, No. 5, 14.08.1987, p. 15-20.

Research output: Contribution to journalArticle

Janicki, Joseph S. ; Shroff, Sanjeev G. ; Weber, Karl. / Physiologic response to the inotropic and vasodilator properties of enoximone. In: The American journal of cardiology. 1987 ; Vol. 60, No. 5. pp. 15-20.
@article{652a998900f143c3bc3269e53c1d2ffa,
title = "Physiologic response to the inotropic and vasodilator properties of enoximone",
abstract = "In patients with chronic cardiac failure, improvement in ventricular function is observed after the administration of enoximone, a phosphodiesterase inhibitor with inotropic and vasodilator properties. The relative contributions of positive inotropy and vasodilation to the improvement in pump performance, however, remain uncertain. Therefore, findings from a series of dog experiments designed to resolve this issue are reviewed. Also, our current understanding of the physiologic response to enoximone in patients with cardiac failure, including the responses of myocardial oxygen consumption and efficiency, are considered. It is concluded that, enoximone produces a substantial (66 ± 2{\%} in dogs) increase in contractility, a relatively minor increase in heart rate (0 to 12{\%}) and a decrease in systemic vascular resistance (-28 to -49{\%}). These are the ranges of average responses based on review of published findings. These physiologic responses lead to an improvement in the pumping function of the failing heart; cardiac output (23 to 83{\%}) and stroke work index (17 to 88{\%}) are increased, and pulmonary capillary wedge pressure (-19 to -59{\%}) and right atrial pressure (-29 to -60{\%}) are decreased. The influence of enoximone on myocardial oxygen consumption is less consistent (-18 to +33{\%}). Nevertheless, enoximone improves the efficiency of the failing heart.",
author = "Janicki, {Joseph S.} and Shroff, {Sanjeev G.} and Karl Weber",
year = "1987",
month = "8",
day = "14",
doi = "10.1016/0002-9149(87)90519-4",
language = "English (US)",
volume = "60",
pages = "15--20",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Physiologic response to the inotropic and vasodilator properties of enoximone

AU - Janicki, Joseph S.

AU - Shroff, Sanjeev G.

AU - Weber, Karl

PY - 1987/8/14

Y1 - 1987/8/14

N2 - In patients with chronic cardiac failure, improvement in ventricular function is observed after the administration of enoximone, a phosphodiesterase inhibitor with inotropic and vasodilator properties. The relative contributions of positive inotropy and vasodilation to the improvement in pump performance, however, remain uncertain. Therefore, findings from a series of dog experiments designed to resolve this issue are reviewed. Also, our current understanding of the physiologic response to enoximone in patients with cardiac failure, including the responses of myocardial oxygen consumption and efficiency, are considered. It is concluded that, enoximone produces a substantial (66 ± 2% in dogs) increase in contractility, a relatively minor increase in heart rate (0 to 12%) and a decrease in systemic vascular resistance (-28 to -49%). These are the ranges of average responses based on review of published findings. These physiologic responses lead to an improvement in the pumping function of the failing heart; cardiac output (23 to 83%) and stroke work index (17 to 88%) are increased, and pulmonary capillary wedge pressure (-19 to -59%) and right atrial pressure (-29 to -60%) are decreased. The influence of enoximone on myocardial oxygen consumption is less consistent (-18 to +33%). Nevertheless, enoximone improves the efficiency of the failing heart.

AB - In patients with chronic cardiac failure, improvement in ventricular function is observed after the administration of enoximone, a phosphodiesterase inhibitor with inotropic and vasodilator properties. The relative contributions of positive inotropy and vasodilation to the improvement in pump performance, however, remain uncertain. Therefore, findings from a series of dog experiments designed to resolve this issue are reviewed. Also, our current understanding of the physiologic response to enoximone in patients with cardiac failure, including the responses of myocardial oxygen consumption and efficiency, are considered. It is concluded that, enoximone produces a substantial (66 ± 2% in dogs) increase in contractility, a relatively minor increase in heart rate (0 to 12%) and a decrease in systemic vascular resistance (-28 to -49%). These are the ranges of average responses based on review of published findings. These physiologic responses lead to an improvement in the pumping function of the failing heart; cardiac output (23 to 83%) and stroke work index (17 to 88%) are increased, and pulmonary capillary wedge pressure (-19 to -59%) and right atrial pressure (-29 to -60%) are decreased. The influence of enoximone on myocardial oxygen consumption is less consistent (-18 to +33%). Nevertheless, enoximone improves the efficiency of the failing heart.

UR - http://www.scopus.com/inward/record.url?scp=0023260860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023260860&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90519-4

DO - 10.1016/0002-9149(87)90519-4

M3 - Article

VL - 60

SP - 15

EP - 20

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -